共 38 条
[1]
Bradley R(2021)Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13864 women in seven randomised trials Lancet Oncol 22 1139-1150
[2]
Braybrooke J(2014)Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors Ther Adv Drug Saf 5 154-166
[3]
Gray R(2022)2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC) Eur Heart J Cardiovasc Imaging 23 e333-465
[4]
Onitilo AA(2020)Impact of stopping trastuzumab in early breast cancer: a population-based study in Ontario, Canada J Natl Cancer Inst 112 1222-1230
[5]
Engel JM(2021)Interventions for preventing cardiotoxicity in breast cancer patients receiving trastuzumab: a systemic review and Bayesian network meta-analysis Front Pharmacol 12 718086-868
[6]
Stankowski RV(2021)Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function Breast Cancer Res Treat 185 863-401
[7]
Lyon AR(2022)Global longitudinal strain: an early marker for cardiotoxicity in patients treated for breast cancer Neth Heart J 77 392-532
[8]
López-Fernández T(2021)Strain-guided management of potentially cardiotoxic cancer therapy J Am Coll Cardiol 26 521-undefined
[9]
Couch LS(2018)Cardio-oncology: an overview on outpatient management and future developments Neth Heart J 9 941148-undefined
[10]
Rushton M(2022)Artificial intelligence applications in cardio-oncology: leveraging high dimensional cardiovascular data Front Cardiovasc Med undefined undefined-undefined